Gain valuable insights into novel therapies, ongoing clinical trials, and future innovations shaping the treatment of ...

Explore seven biotech companies advancing clinical drugs in the race for regulatory approval to revolutionize hepatitis B ...

It's not often a famous composer helps solve a 200-year-old mystery, but DNA from Beethoven's hair might actually do that.

The Food and Drug Administration (FDA) has granted Fast Track designation to PBGENE-HBV, an investigational gene editing therapy for adults with chronic hepatitis B.

According to WHO, 254 million people globally were estimated to have HBV in 2022, but only approximately 10% had been ...

Virus-specific T-cell measurement is made easier to enable better understanding of immune responses in patients and ...

China: A recent retrospective cohort study has highlighted the significant role of pulmonary infections in influencing ...

Precision BioSciences stock soars 24% as the FDA grants the Fast Track designation to its PBGENE-HBV gene therapy for potentially curing chronic hepatitis B.

Precision BioSciences (DTIL) announced that the FDA has granted fast track designation for PBGENE-HBV, the company’s lead wholly owned in vivo ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine ...

Currently, there is no feline vaccine for the hepatitis B virus, and the hepatitis B vaccine for humans is highly toxic to ...

Somchai, a Thai native, was 21 years old and faced a double threat to his long-term health and wellbeing. He was living with ...